Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nexavar sorafenib: Phase III data

In a double-blind, Asian Phase III trial in 226 patients, Nexavar significantly improved overall survival vs. placebo.

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE